For example, the prostate cancer medicine, abiraterone, was routinely available in Wales from February 2012 following appraisal by AWMSG.
Er enghraifft, roedd abiraterone, sef meddyginiaeth ar gyfer canser y brostad, ar gael yng Nghymru fel mater o drefn o Chwefror 2012 ymlaen ar ôl iddo gael ei werthuso gan AWMSG.